Sentynl TherapeuticsThe journey to finding a diagnosis for children with rare conditions is often fraught with challenges, placing a significant emotional and financial burden on patients and their families. Early diagnosis is a key factor in finding effective treatments and determining better health outcomes for patients with rare diseases. On average, it takes 4.8 years to diagnose a rare disease, but next-generation sequencing can cut this down to weeks or even days. As families welcome new additions, choosing to screen newborns for both common and rare diseases is a critical step in establishing a healthier future for this next generation.
The Toll of the Journey Toward Diagnosis
Having a child with an unknown medical condition can put tremendous strain on families. The often-yearslong journey toward finding an answer is typically filled with countless doctors’ visits, tests, and interventions that don’t result in improved outcomes – each of which takes a significant toll in terms of time, money, and stress. Consider this – the economic impact of a delayed rare disease diagnosis is up to $517,000 in avoidable costs per patient. Next-generation sequencing offers families a crucial opportunity to receive early and definitive results, helping them understand their child’s condition sooner. This can help them avoid the stress of endless searching and focus on finding effective ways to manage the condition.
Approximately 80% of rare diseases have a genetic cause, and about 70% appear in childhood, meaning that many of these conditions can be detectable from birth. Genetic testing for newborns enables clinicians and families to identify diseases preemptively, even if symptoms have not yet revealed themselves. With just a few drops of blood, genetic testing provides a clear diagnosis, sparing families from years of costly tests and the stress of searching for answers. Moreover, next-generation sequencing can screen for thousands of conditions simultaneously, drastically reducing diagnosis times to a matter of weeks or even days. Early diagnosis opens the door to earlier intervention and provides patients with the opportunity to access emerging therapies and clinical trials, offering new hope for conditions once believed to be untreatable or unmanageable.
How We Got Here: The Genetic Testing Revolution
Advancements in research have significantly improved the ability to diagnose and treat rare diseases. One of the most promising developments is the increasing effectiveness of genetic testing, which has grown exponentially since the completion of the Human Genome Project (HGP). This international research initiative, which mapped the entire human genome, started in 1990 and culminated in 2003. Its findings have significantly increased the ability to identify rare diseases that were difficult to diagnose previously, enabling more timely and accurate treatment.
One key advancement in genetic testing is whole-genome sequencing (WGS), which, unlike previous methods, offers high sensitivity and specificity in identifying rare disorders. On top of this, rapid whole-genome sequencing (rWGS) is an emerging alternative to standard WGS, which has the potential to provide expedited results in under 50 hours compared to several weeks for WGS. By driving earlier diagnoses, WGS and especially rWGS are empowering clinicians to make timely and personalized treatment decisions which is improving the standard of care for rare disease patients and their families.
Sentynl Therapeutics: Leading the Way in Rare Disease Therapy
Two of the most important pieces in enabling a healthier future for patients with rare disease are facilitating early and rapid genome sequencing and developing a care plan that helps them effectively manage their condition.
Sentynl Therapeutics provides a model for how biopharmaceutical companies in the rare disease space can help patients and families achieve both of these goals in an efficient and compliant manner. A vital first step in identifying the right care program for patients is getting a conclusive diagnosis, which is why Sentynl is a founding member of the BeginNGS® research consortium. The consortium, led by Rady Children’s Institute for Genomic Medicine, offers all infants and their families screening for hundreds of early onset, treatable genetic conditions that primarily impact newborns and infants and are not included in standard biochemical newborn screening. Programs such as these are playing a critical role in expanding research, awareness, and access to advanced genetic screening for rare diseases in newborns.
The Future of Rare Disease Diagnosis
Rare conditions are not actually rare when you consider how many there are, and chances are you know someone who is impacted by a rare disease in some way. With companies like Sentynl Therapeutics playing a vital role in driving increased awareness in rare diseases and newborn genetic screening and access to rare disease therapies, the future has never looked brighter for rare disease patients in Generation Beta. As gene sequencing technology continues to advance, we can achieve earlier diagnoses with the goals of earlier access to treatment and healthier patients and families.
